The FDA Endocrinologic and Metabolic Drugs Advisory Committee does not recommend Zetia (ezetimibe) from Merck, voting 10-5 against expanding the...
A US Federal judge has ruled in two jointly related patent infringement suits against Mylan that a patent on hypolipaemic...
Merck Inc. announced that the FDA has issued a Complete Response Letter regarding Merck's Supplemental New Drug Applications for Zetia...
Alirocumab from Regeneron + Sanofi, helped 10 times as many high-risk patients unable to tolerate widely-used statins get their "bad"...
NICE has published revised draft guidance on Ezetrol (ezetimibe), from Merck Inc, that in essence reverts to the guidance being...
Merck announced that the New England Journal of Medicine published the results of the IMPROVE-IT trial, an investigational study comparing...
Merck has announced that the investigational IMPROVE-IT study met its primary and all secondary composite efficacy endpoints. In IMPROVE-IT, patients...
A meta-analysis by Sabatine and colleagues published in JAMA Cardiology on 1 August 2018 supports not only a return to...